ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION17 JULY 2024 at 8.30 EEST Inside information: Phase III ARANOTE…
After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; p <…
ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients…
Subtle Medical's new software is now available for clinical use in the US, further redefining the speed and quality of…
After several years of development, the company's first dedicated brain PET system comes to market in the US. ZURICH, July…
Live video webcast with Chief Executive Officer, John Climaco, on Wednesday, June 17th at 4:00 PM ET HOUSTON, TX /…
LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs…
July 16, 2024 Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada Biodexa Pharmaceuticals…
Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to CalidiSAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE)…
On track to initiate Phase 1b/2a clinical trial of AB126 in acute ischemic stroke in 2H 2024BOSTON and ATHENS, Ga.,…
